Wednesday, March 23rd, 2016 - WiseGuyReports

WiseGuyReports.com adds new report on “Global Autoimmune Drugs Market 2016-2020” with table and figures on its research store.

The research analysts forecast the global autoimmune diseases drugs market to grow at a CAGR of 5.57% during the period 2016-2020.

Autoimmune diseases are immunological disorders that occur when the immune system attacks and destroys healthy tissues in the body rather than foreign bodies, causing significant pain, inflammation, and organ damage. These diseases can affect the nervous system, cardiovascular system, and musculoskeletal system or individual organs, including the skin, lungs, kidneys, glands, and joints.

Autoimmune diseases occur due to genetic, infectious, or environmental factors. There are over 80 autoimmune diseases, including AS, IBD (CD and UC), MS, RA, SLE, and PsA. DMARDs, NSAIDs, corticosteroids, analgesics, and immunosuppressants are the major drug classes used to treat autoimmune diseases.

Complete Report Details at https://www.wiseguyreports.com/reports/global-autoimmune-drugs-market-2016-2020

For more information or any query mail at [email protected]

Covered in this report
The report covers the present scenario and the growth prospects of the global autoimmune diseases drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of autoimmune diseases.

The market is divided into the following segments based on geography:
• Americas 
• APAC 
• EMEA

The report, Global Autoimmune Diseases Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Order a Purchase License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=373092 .

For more information or any query mail at [email protected]

Key vendors
• AbbVie Inc.
• Amgen Inc.
• Biogen
• F. Hoffmann-La Roche
• Johnson & Johnson Private Limited
• Pfizer Inc.

Other prominent vendors
• Ablynx
• AB Science
• Acorda Therapeutics
• Alder BioPharmaceuticals
• Antares Pharma
• Astellas Pharma
• AstraZeneca
• Baxter
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Celltrion
• ChemoCentryx
• Coherus BioSciences
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Gilead Sciences
• GSK
• Hospira
• Idera Pharmaceuticals
• Immunomedics
• ImmuPharma
• Incyte
• Invion
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• MedImmune
• Morphotek
• Novo Nordisk
• Novartis
• Opexa Therapeutics
• Principia Biopharma
• Regeneron Pharmaceuticals
• Sandoz
• Sanofi
• Santarus
• Takeda Pharmaceuticals
• UCB
• Vaccinex
• Vertex Pharmaceuticals
• Vitae Pharmaceuticals

List of Exhibits 
Exhibit 01: Product offerings 
Exhibit 02: Etiology of autoimmune diseases 
Exhibit 03: Signs and symptoms of autoimmune diseases 
Exhibit 04: Diagnostic methods for autoimmune diseases 
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases 
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases 
Exhibit 07: Top drugs for autoimmune diseases 
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions) 
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions) 
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions) 
Exhibit 11: Prevalence and incidence of SLE 
Exhibit 12: Pipeline molecules for RA 
Exhibit 13: Pipeline molecules for MS 
Exhibit 14: Pipeline molecules for PsA 
Exhibit 15: Pipeline molecules for CD 
Exhibit 16: Pipeline molecules for UC 
Exhibit 17: Pipeline molecules for SLE 
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions) 
Exhibit 19: Five forces analysis 
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease 
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015 
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020 
Exhibit 23: Global RA drugs market 2015-2020 ($ billions) 
Exhibit 24: Global RA drugs market by drug class 2015 
Exhibit 25: Top-vendor offerings for global RA drugs market 
Exhibit 26: RA clinical trial by Phase 2015 
Exhibit 27: RA clinical trial by status 2015 
Exhibit 28: Drivers and challenges of global RA drugs market 
Exhibit 29: Global MS drugs market 2015-2020 ($ billions) 
Exhibit 30: Global MS drugs market by molecule type 2015 
Exhibit 31: Top-vendor offerings for global MS drugs market 
Exhibit 32: Drivers and challenges of global MS drugs market 
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions) 
Exhibit 34: Global PsA drugs market segmentation by MOA 2015 
Exhibit 35: Top-vendor offerings for global PsA drugs market 
Exhibit 36: Drivers and challenges of global PsA drugs market 
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions) 
Exhibit 38: Global IBD drugs market by type of disease 2015 
Exhibit 39: Global IBD drugs market by drug class 2015 
Exhibit 40: Top-vendor offerings for global IBD drugs market 
Exhibit 41: Drivers and challenges of global IBD drugs market 
Exhibit 42: Global AS drugs market 2015-2020 ($ billions) 
Exhibit 43: Global AS drugs market by MOA 2015 
Exhibit 44: Top-vendor offerings for global AS drugs market 
Exhibit 45: Drivers and challenges of global AS drugs market 
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions) 
Exhibit 47: Drivers and challenges of global SLE drugs market 
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA 
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015 
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015 
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class 
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases 
Exhibit 53: NSAIDs used to treat autoimmune diseases 
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015 
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule 
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions) 
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions) 
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015 
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA 
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015 
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form 
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015 
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015 
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions) 
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions) 
Exhibit 66: Autoimmune diseases drugs market in America by country 2015 
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions) 
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US 
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions) 
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions) 
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions) 
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan 
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions) 
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions) 
Exhibit 75: Population aged 60 years and over ($ millions) 
Exhibit 76: Biologics approval timeline by US FDA 
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases 
Exhibit 78: Impact of drivers 
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions) 
Exhibit 80: Approval and patent expiries of top selling biologics 
Exhibit 81: CAM therapies for autoimmune diseases 
Exhibit 82: Usage of CAM therapies among individuals in US 2014 
Exhibit 83: Adverse effects associated with autoimmune disease therapies 
Exhibit 84: Impact of drivers and challenges 
Exhibit 85: Patient assistance programs for autoimmune diseases drugs 
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015 
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions) 
Exhibit 88: AbbVie: Product segmentation by revenue 20150 
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions) 
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions) 
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions) 
Exhibit 92: Sales of HUMIRA in major markets 
Exhibit 93: AbbVie: Key takeaways 
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014 
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions) 
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions) 
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions) 
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions) 
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions) 
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions) 
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions) 
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions) 
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions) 
Exhibit 104: Johnson & Johnson: Key takeaways 
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015 
Exhibit 106: Top selling autoimmune diseases drugs 
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions) 
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions) 
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions) 
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions) 
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions) 
Exhibit 112: Biogen: Key takeaways 
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions) 
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions) 
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions) 
Exhibit 116: Amgen: Key takeaways 
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014 
Exhibit 118: Top selling autoimmune diseases drugs 
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions) 
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions) 
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions) 
Exhibit 122: Pfizer: Key takeaways 
Exhibit 123: Top selling autoimmune diseases drugs 
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions) 
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155 
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions) 
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions) 
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015 
Exhibit 129: F. Hoffmann-La Roche: Key takeaways

Inquire for Discount @ https://www.wiseguyreports.com/check_discount/global-autoimmune-drugs-market-2016-2020 .

Contact for More Information at [email protected] or +1 (646) 845 9349 (US) and +44 208 133 9349 (UK)

Contact Profile

WiseGuyReports


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.


Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349
W: www.wiseguyreports.com/

Keywords

Autoimmune Drugs, Autoimmune Drugs Market, Autoimmune Drugs Industry, Autoimmune Drugs Market Trends, Autoimmune Drugs Market Share, Autoimmune Drugs Market Size, Autoimmune Drugs Market Analysis, Autoimmune Drugs Industry Growth, Autoimmune Drugs Industr

Categories

Newsrooms

Sharing

More Formats